Skip to main content
letter
. 2022 Aug 28;12(8):e993. doi: 10.1002/ctm2.993

FIGURE 3.

FIGURE 3

Colonic IL‐18 activation is involved in RAI16 deficiency‐induced colitis and associated CAC progression. (A) IL‐1β, IL‐18, IL‐6 and TNF‐α levels were measured in colon explants from WT and RAI16–/– mice with or without DSS treatment by ELISA. (B) The procession of IL‐18 was determined in colon tissues from WT and RAI16–/– mice with or without DSS treatment by immunoblot. (C) IL‐18 level was measured in supernatant of WT and RAI16–/– IECs with or without DSS treatment by ELISA. (D–H) Mice was intraperitoneally injected a neutralising IL‐18 antibody (anti‐IL‐18,) or control antibody (IgG) every 2 days for 3 times during DSS treatment. Body weight loss (D), disease activity index (E), colon length (F) and histopathology (G) were determined as before. (I–O) Mice were intraperitoneally injected a neutralising IL‐18 antibody (anti‐IL‐18) or control antibody (IgG) once a week for 14 weeks. Tumour number (I), tumour size (J) and tumour grade (K) were analysed on day 100.